Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer Atezolizumab data from clinical trials in non–small-cell lung cancer, metastatic urothelial carcinoma, ...

The first, formal revision of specific guidelines, known as RECIST, used by clinicians to measure tumour size and response to treatment, has been published today (Tuesday 20 January) in a special ...

Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in ...

Therapeutics, a clinical-stage biotechnology company, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase 1/2 trial of PARG inhibitor ETX-19477. These data will ...

In addition to the unique side effect profile, ipilimumab is associated with novel patterns of clinical response, distinct from those observed with traditional cytotoxic chemotherapy. Cytotoxic ...